Skip to main content Accessibility help
×
×
Home

Anti-parasitic effect of novel amidines against Trypanosoma cruzi: phenotypic and in silico absorption, distribution, metabolism, excretion and toxicity analysis

  • ALINE SILVA DA GAMA NEFERTITI (a1), MARCOS MEUSER BATISTA (a1), PATRÍCIA BERNARDINO DA SILVA (a1), EDUARDO CAIO TORRES-SANTOS (a2), EDEZIO F. CUNHA-JÚNIOR (a2), JULIUS GREEN (a3), ARVIND KUMAR (a3), ABDELBASSET A. FARAHAT (a3) (a4), DAVID WILSON BOYKIN (a3) and MARIA DE NAZARE CORREIA SOEIRO (a1)...

Summary

New more selective and potent drugs are urgently need to treat Chagas disease (CD). Among the many synthetic compounds evaluated against Trypanosoma cruzi, aromatic amidines (AAs) and especially arylimidamides (AIAs) have potent activity against this parasite. Presently, the effect of four mono-amidines (DB2228, DB2229, DB2292 and DB2294), four diamidines (DB2232, DB2235, DB2251 and DB2253) and one AIA (DB2255) was screened in vitro against different forms (bloodstream trypomastigotes – BT and intracellular forms) and strains from discrete typing unit (DTU) I and VI of T. cruzi and their cytotoxic profile on mammalian host cells. Except for DB2253, all molecules were as active as benznidazole (Bz), resulting in 50% of reduction in the number of alive BT, with EC50 ranging from 2·7 to 10·1 µ m after 24 h of incubation. DB2255 was also the most potent against amastigotes (Tulahuen strain) showing similar activity to that of Bz (3 µ m). In silico absorption, distribution, metabolism, excretion and toxicity analysis demonstrated probability of human intestinal adsorption, while mutagenicity and inhibition of hERG1 were not predicted, besides giving acceptable predicted volumes of distribution. Our findings contribute for better knowledge regarding the biological effect of this class of aromatic molecules against T. cruzi aiming to identify novel promising agent for CD therapy.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Anti-parasitic effect of novel amidines against Trypanosoma cruzi: phenotypic and in silico absorption, distribution, metabolism, excretion and toxicity analysis
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Anti-parasitic effect of novel amidines against Trypanosoma cruzi: phenotypic and in silico absorption, distribution, metabolism, excretion and toxicity analysis
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Anti-parasitic effect of novel amidines against Trypanosoma cruzi: phenotypic and in silico absorption, distribution, metabolism, excretion and toxicity analysis
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

Corresponding author

*Corresponding author: Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, 4365 Manguinhos, Rio de Janeiro, Brazil. E-mail: soeiro@ioc.fiocruz.br

References

Hide All
Albajar-Viñas, P. and Dias, J. C. (2014). Advancing the treatment for Chagas’ disease. New England Journal of Medicine 15, 19421943.
Batista, D. G., Batista, M. M., de Oliveira, G. M., do Amaral, P. B., Lannes-Vieira, J., Britto, C. C., Junqueira, A., Lima, M. M., Romanha, A. J., Sales Junior, P. A., Stephens, C. E., Boykin, D. W. and Soeiro, M. N. (2010). Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas’ disease treatment. 2010. Antimicrobial Agents and Chemotherapy 54, 29402952.
Bilbe, G. (2015). Infectious diseases. Overcoming neglect of kinetoplastid diseases. Science 29, 974976.
Buckner, F. S., Verlinde, C. L. M. J., La Flamme, A. C. and van Voorhis, W. C. (1996). Efficient technique for screening drugs activity against Trypanosoma cruzi using parasites expressing β-galactosidase. Antimicrobial Agents and Chemotherapy 40, 25922597.
Chatelain, E. (2015). Chagas disease drug discovery: toward a new era. Journal of Biomolecular Screening 20, 2235.
Chatelain, E. and Konar, N. (2015). Translational challenges of animal models in Chagas disease drug development: a review. Journal of Drug Design Development and Therapy 19, 48074823.
Coura, J. R. and Dias, J. C. (2015). Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Memórias do Instituto Oswaldo Cruz 104(Suppl.), 3140.
De Araújo, J. S., Da Silva, C. F., Batista, D. G., Da Silva, P. B., Meuser, M. B., Aiub, C. A., da Silva, M. F., Araújo-Lima, C. F., Banerjee, M., Farahat, A. A., Stephens, C. E., Kumar, A., Boykin, D. W. and Soeiro, M. N. (2014). In vitro and in vivo studies of the biological activity of novel arylimidamides against Trypanosoma cruzi . Antimicrobial Agents and Chemotherapy 58, 41914195.
De Souza, E. M., Lansiaux, A., Bailly, C., Wilson, W. D., Hu, Q., Boykin, D. W., Batista, M. M., Araújo-Jorge, T. C. and Soeiro, M. N. (2004). Phenyl substitution of furamidine markedly potentiates its anti-parasitic activity against Trypanosoma cruzi and Leishmania amazonensis . Biochemical Pharmacology Journal 15, 593600.
Díaz, M. V., Miranda, M. R., Campos-Estrada, C., Reigada, C., Maya, J. D., Pereira, C. A. and López-Muñoz, R. (2014) Pentamidine exerts in vitro and in vivo anti Trypanosoma cruzi activity and inhibits the polyamine transport in Trypanosoma cruzi . Acta Tropica Journal 134, 19.
Diniz, L. de F., Caldas, I. S., Guedes, P. M., Crepalde, G., de Lana, M., Carneiro, C. M., Talvani, A., Urbina, J. A. and Bahia, M. T. (2010). Effects of ravuconazole treatment on parasite in dogs experimentally Infected with Trypanosoma cruzi. Antimicrobial Agents and Chemotherapy 54, 29792986.
Don, R. and Ioset, J. R. (2013). Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology 141, 140146.
Drugs for Neglected Diseases Initiave (2016). Chagas Disease Target Product Profile. http://www.dndi.org/diseases-projects/portfolio.html (accessed June 4, 2016).
Farahat, A. A., Paliakov, E., Kumar, A., Barghash, A. E., Goda, F. E., Eisa, H. M., Wenzler, T., Brun, R., Liu, Y., Wilson, W. D. and Boykin, D. W. (2011). Exploration of larger central ring linkers in furamidine analogues: synthesis and evaluation of their DNA binding, antiparasitic and fluorescence properties. Bioorganic and Medicinal Chemistry 1, 21562167.
Francisco, A. F., Lewis, M. D., Jayawardhana, S., Taylor, M. C., Chatelain, E. and Kelly, J. M. (2015). Limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging. Antimicrobial Agents and Chemotherapy 59, 46534661.
Green, J. (2014). Synthesis of aza-heterocyclic monoamidines as potential DNA minor groove binders, anti-trypanosomals, and boron neutron capture therapy agents. Dissertation, Georgia State University. http://scholarworks.gsu.edu/chemistry_diss/101.
Ismail, M. A., Brun, R., Wenzler, T., Tanious, F. A., Wilson, W. D. and Boykin, D. W. (2004). Dicationic biphenyl benzimidazole derivatives as antiprotozoal agents. Bioorganic and Medicinal Chemistry 15, 54055413.
Keenan, M. and Chaplin, J. H. (2015). A new era for chagas disease drug discovery? Progress in Medicinal Chemistry 54, 185230.
King, H., Lourie, E. M. and Yorke, W. (1937). New trypanocidal substances. Lancet 230, 1360–1136.
Marin-Neto, J. A., Rassi, A. Jr., Morillo, C. A., Avezum, A., Connolly, S. J., Sosa-Estani, S., Rosas, F., Yusuf, S. and Benefit, I. (2008). Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas’ cardiomyopathy: the benznidazole evaluation for interrupting trypanosomiasis (BENEFIT). American Heart Journal 156, 3743.
Meirelles, M. N., de Araujo-Jorge, T. C., Miranda, C. F., de Souza, W. and Barbosa, H. S. (1986). Interaction of Trypanosoma cruzi with heart muscle cells: ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitro. European Journal of Cell Biology 41, 198206.
Molina, I., Gómez, i Prat.J., Salvador, F., Treviño, B., Sulleiro, E., Serre, N., Pou, D., Roure, S., Cabezos, J., Valerio, L., Blanco-Grau, A., Sánchez-Montalvá, A., Vidal, X. and Pahissa, A. (2014). Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. New England Journal of Medicine 15, 18991908.
Morillo, C. A., Marin-Neto, J. A., Avezum, A., Sosa-Estani, S., Rassi, A. Jr., Rosas, F., Villena, E., Quiroz, R., Bonilla, R., Britto, C., Guhl, F., Velazquez, E., Bonilla, L., Meeks, B., Rao-Melacini, P., Pogue, J., Mattos, A., Lazdins, J., Rassi, A., Connolly, S. J., Yusuf, S. and BENEFIT, I. (2015). Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. New England Journal of Medicine 373, 12951306.
Patterson, S. and Wyllie, S. (2014). Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects. Trends in Parasitology 30, 289298.
Pires, D. E., Blundell, T. L. and Ascher, D. B. (2015). pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicine Chemistry 14, 40664072.
Romanha, A. J., Castro, S. L., Soeiro, M. N., Lannes-Vieira, J., Ribeiro, I., Talvani, A., Bourdin, B., Blum, B., Olivieri, B., Zani, C., Spadafora, C., Chiari, E., Chatelain, E., Chaves, G., Calzada, J. E., Bustamante, J. M., Freitas-Junior, L. H., Romero, L. I., Bahia, M. T., Lotrowska, M., Soares, M., Andrade, S. G., Armstrong, T., Degrave, W. and Andrade, Z. A. (2010). In vitro and in vivo experimental models for drug screening and development for Chagas disease. Memórias do Instituto Oswaldo Cruz 105, 233238.
Simões-Silva, M. R., Nefertiti, A. S. G., De Araújo, J. S., Batista, M. M., Da Silva, P. B., Bahia, M. T., Menna-Barreto, R. S., Pavão, B. P., Green, J., Farahat, A. A., Kumar, A., Boykin, D. W. and Soeiro, M. N. C. (2016). Phenotypic screening in vitro of novel aromatic amidines against Trypanosoma cruzi . Antimicrobial Agents and Chemotherapy 60, 47014707.
Soeiro, M. N., de Castro, S. L., de Souza, E. M., Batista, D. G., Silva, C. F. and Boykin, D. W. (2008). Diamidine activity against trypanosomes: the state of the art. Current Molecular Pharmacology 1, 151161.
Soeiro, M. N., Werbovetz, K., Boykin, D. W., Wilson, W. D., Wang, M. Z. and Hemphill, A. (2013). Novel amidines and analogues as promising agents against intracellular parasites: a systematic review. Parasitology 140, 929951.
Stephens, C. E., Tanious, F., Kim, S., Wilson, W. D., Schell, W. A., Perfect, J. R., Franzblau, S. G. and Boykin, D. W. (2001). Diguanidino and “reversed” diamidino 2,5-diarylfurans as antimicrobial agents. Journal of Medicinal Chemistry 24, 17411748.
Teixeira, A. R., Nascimento, R. J. and Sturm, N. R. (2006). Evolution and pathology in chagas disease–a review. Memórias do Instituto Oswaldo Cruz 101, 463491.
Timm, B. L., da Silva, P. B., Batista, M. M., da Silva, F. H., da Silva, C. F., Tidwell, R. R., Patrick, D. A., Jones, S. K., Bakunov, S. A., Bakunova, S. M. and Soeiro, M. N. (2014). In vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruzi . Antimicrobial Agents and Chemotherapy 58, 37203726.
Urbina, J. A., Payares, G., Contreras, L. M., Liendo, A., Sanoja, C., Molina, J., Piras, M., Piras, R., Perez, N., Wincker, P. and Loebenberg, D. (1998). Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrobial Agents and Chemotherapy 42, 17711777.
Wilkinson, S. R. and Kelly, J. M. (2009). Trypanocidal drugs: mechanisms, resistance and new targets. Expert Reviews in Molecular Medicine Journal 11, 125.
Wilkinson, S. R., Taylor, M. C., Horn, D., Kelly, J. M. and Cheeseman, I. A. (2008). A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proceedings of the National Academy of Sciences of the United States of America 105, 50225027.
World Health Organization (2016). What is Chagas Disease? (WHO) Third WHO Report on Neglected Tropical Diseases. Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva.
Zingales, B., Andrade, S. G., Briones, M. R., Campbell, D. A., Chiari, E., Fernandes, O., Guhl, F., Lages-Silva, E., Macedo, A. M., Machado, C. R., Miles, M. A., Romanha, A. J., Sturm, N. R., Tibayrenc, M., Schijman, A. G. and Second Satellite Meeting (2009). A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Memórias do Instituto Oswaldo Cruz 104, 10511054.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Parasitology Open
  • ISSN: -
  • EISSN: 2055-7094
  • URL: /core/journals/parasitology-open
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed